Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼öµÎÁõÀ» µ¿¹ÝÇÑ ¼ö¸ð¼¼Æ÷Á¾¿¡¼­ ³úô¼ö¾× ´Ü¶ô¼úÀÇ Çʿ伺¿¡ ´ëÇÑ ¿¹ÈÄÀÎÀÚ Prognostic Factors for Shunting in Medulloblastoma Combined with Hydrocephalus

´ëÇѽŰæ¿Ü°úÇÐȸÁö 1998³â 27±Ç 3È£ p.363 ~ 368
¼Ò¼Ó »ó¼¼Á¤º¸
±èÀç°Ç/Jae Keon Kim Á¤µµ¼·/È«¿ë±æ/¾Èâȣ/¹Ú¿µ¼·/°­Áرâ/Dong Sup Chung/Yong Kil Hong/Chang Ho Ahn/Young Sup Park/Joon Ki Kang

Abstract

¼­·Ð
¼ö¸ð¼¼Æ÷Á¾Àº ¼Ò¾ÆÀÇ ÈĵοͿ¡ »ý±â´Â °¡Àå ÈçÇÑ Á¾¾çÀÇ Çϳª·Î, ÈçÈ÷, ³úô¼ö¾×ÀÇ °æ·Î¸¦
¸·¾Æ¼­ ¼öµÎÁõÀ» À¯¹ßÇÑ´Ù
ÈÄµÎ¿Í Á¾¾çÀ» °¡Áø ȯÀÚ¿¡ À־ ¼ö¼úÀÇ ÀÌȯÀ²(morbidity) ¹× »ç¸Á·ü(mortality)Àº Á¾
¾çÀ¸·Î ÀÎÇÑ Áõ»ó»Ó¸¸ ¾Æ´Ï¶ó ÀÌÂ÷ÀûÀ¸·Î ³ªÅ¸³ª´Â ¼öµÎÁõ°úµµ ¸Å¿ì ¹ÐÁ¢ÇÑ °ü°è¸¦ °¡Áö°í
ÀÖ´Ù. Raimondi¿Í Tomita°¡ ÈÄµÎ¿Í Á¾¾çÀ» °¡Áø ȯÀÚ´Â Á¾¾ç°ú ¼öµÎÁõÀ̶ó´Â µÎ °¡Áö Áúȯ
À» °®°í ÀÖ´Â °ÍÀ¸·Î °£ÁÖÇÒ ¼ö ÀÖ´Ù°í ÇÒ¸¸Å­ ÈÄµÎ¿Í Á¾¾çÀÇ Ä¡·á¿¡ À־ ¼öµÎÁõÀ» ¾î¶»
°Ô ÇØ°áÇÒ °ÍÀΰ¡ ÇÏ´Â ¹®Á¦´Â Á¾¾ç ÀÚüÀÇ Ä¡·á¿¡ ¸øÁö ¾Ê°Ô Áß¿äÇÑ ¹®Á¦¿´´Ù. Albright¿Í
ReigelÀº ÈÄµÎ¿Í Á¾¾çÀ» °¡Áø ȯÀÚ¿¡¼­ Á¾¾çÀ» Á¦°ÅÇϱâ Àü¿¡ ³úô¼ö¾× ´Ü¶ô¼úÀ» ½ÃÇàÇÏ¿´
´õ´Ï ¼ö¼úÀÇ ÀÌȯÀ²°ú »ç¸ÁÀ²ÀÌ ÇöÀúÇÏ°Ô °¨¼ÒµÇ¾ú´Ù°í ÇÏ¿´À¸³ª, ±× ÀÌÈÄ Áø´Ü ¹æ¹ýÀÇ ¹ß
ÀüÀ¸·Î ÀÎÇØ Á¾¾çÀÇ Á¶±â Áø´ÜÀÌ °¡´ÉÇØÁ³°í ½ºÅ×·ÎÀ̵åÀÇ »ç¿ë µîÀ¸·Î ÀÎÇØ ³ú¾Ð »ó½ÂÀÇ
Á¶ÀýÀÌ ºñ±³Àû ½±°Ô ÀÌ·ç¾îÁú ¼ö ÀÖ¾î. Á¾¾çÁ¦°Å¼ú Àü¿¡ ¹Ì¸® ½ÃÇàÇÏ´Â ³úô¼ö¾× ´Ü¶ô¼úÀÇ
°¡Ä¡¿¡ ´ëÇØ Àǹ®À» °®´Â º¸°íµéÀÌ ¹ßÇ¥µÇ¾ú´Ù
±Ù·¡¿¡´Â ¼ö¸ð¼¼Æ÷Á¾ ȯÀÚÀÇ 20¡­40%¸¸ÀÌ Á¾¾çÁ¦°Å ÈÄ ³úô¼ö¾× ´Ü¶ô¼úÀÌ ÇÊ¿äÇÑ °ÍÀ¸·Î
º¸°íµÇ°í ÀÖ´Ù.
µû¶ó¼­ ¸ðµç ¼ö¸ð¼¼Æ÷Á¾ ȯÀڵ鿡°Ô ¿µ±¸ÀûÀÎ ³úô¼ö¾× ´Ü¶ô¼úÀÌ ÇÊ¿äÇÑ °ÍÀº ¾Æ´ÏÁö¸¸,
¾ÆÁ÷µµ ÀûÁö ¾ÊÀº ¼öÀÇ È¯Àڵ鿡°Ô´Â Á¾¾çÁ¦°Å¼ú ÈÄ¿¡ ³úô¼ö¾× ´Ü¶ô¼úÀÌ ÇÊ¿äÇÑ °ÍÀÌ »ç½Ç
ÀÌ´Ù ÀÌ¿Í °ü·ÃµÈ ÀÎÀÚµé, Áï ³úô¼ö¾× ´Ü¶ô¼úÀÌ ÇÊ¿äÇÒ °ÍÀ¸·Î ¿¹ÃøÇÒ ¼ö ÀÖ´Â ÀÎÀÚµéÀ»
¹Ì¸® ¾Ë ¼ö ÀÖ´Ù¸é, ³úô¼ö¾× ¿ìȸ¼úÀÌ ´Ê¾îÁ®¼­ ¿Ã ¼ö ÀÖ´Â ¿©·¯ °¡Áö ÇÕº´Áõ°ú ÀÌ¿Í ¹Ý´ë
·Î ºÒÇÊ¿äÇÏ°Ô ³úô¼ö¾× ´Ü¶ô¼úÀ» ½ÃÇàÇÔÀ¸·Î½á ¿Ã ¼ö ÀÖ´Â ¿©·¯ °¡Áö ÇÕº´ÁõÀ» ÁÙÀÏ ¼ö ÀÖ
À» °ÍÀ¸·Î »ý°¢µÇ¾î º» Á¶»ç¸¦ ½ÃÇàÇÏ¿´´Ù.
#ÃÊ·Ï#
The majority of patients with medulloblastoma present with hydrocephalus, It has
been reported, however, that not all medullobalstoma patients will continue to have
hydrocephalus after the tumor is resected, and in fact, only selected patients need
permanent shunts. To retrospectively identify the prognostic factors indicating this
requirement, we analysed several characteristics in patients without preoperative shunts
suffering from medulloblastoma combined with hydrocephalus, We studied 32 patients
and divided them into two groups : those requiring shunts within 4 weeks of surgery,
and those not shunted. Nine patients(28%) required a permanent shunt. We found that
these patients were younger(4.8¡¾4.3 vs. 9.6¡¾7.4 years ; p<0.05), had more extensive
tumors(Chang's stage T2 vs. T3 ; P<0.05), and that postoperatively, some tumor
remained(p<0.05). However, with regard to gender, symptoms of increased intracranial
pressure(ICP), the duration of these symptoms, positive cerebrospinal fluid(CSF)
cytology, perioperative external ventricular drainge, and degree of preoperative
hydrocephalus, there were no differences between the groups.
It was thus concluded that younger patients with extensive preoperative tumors and
tumors remaining after surgery may benefit from postoperative CSF diversion. It was
thought that patients not fitting the above criteria can probably be managed with
perioperative corticosteroids alone.

Å°¿öµå

Medulloblastoma; Hydrocephalus; Prognostic factors; Permanent shunt;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS